The inclusion of SS-31 or other mitochondria-targeted compounds in a multimodal therapeutic protocol based on ghrelin analogues could improve muscle function and mass, respectively, thus more effectively benefiting cachectic cancer patients. This evidence concerns the gene GHRL and cancer.